您好，欢迎来到化工原料网！ [登录] [免费注册]
化工原料网
发布求购
位置：首页 > 产品库 > Luzopeptin A
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
Luzopeptin A
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
Luzopeptin A图片
CAS NO:75580-37-9
包装与价格：
包装价格(元)
1mg电议
5mg电议

产品介绍

化学性质

Physical AppearanceA tan solid
StorageStore at -20°C
M.Wt1427.4
Cas No.75580-37-9
FormulaC64H78N14O24
SynonymsBBM-928A
SolubilitySoluble in DMSO;Soluble in dimethyl formamide
Chemical NameLuzopeptin A
Canonical SMILESCC(O[C@@H]1[C@@](N2N=CC1)([H])C(NCC(N(C)CC(N(C)[C@@H](C(O)(C)C)C(OC[C@@H](NC(C3=NC4=CC=C(OC)C=C4C=C3O)=O)C(N5[C@]([C@@H](OC(C)=O)CC=N5)([H])C(NCC(N(C)CC(N(C)[C@@H](C(O)(C)C)C(OC[C@@H](NC(C6=NC(C=CC(OC)=C7)=C7C=C6O)=O)C2=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=
运输条件蓝冰运输或根据您的需求运输。
一般建议为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。

资料参考

Luzopeptin A is a cyclic depsipeptide antibiotic.

A depsipeptide is a peptide in which one or more of its amide groups are replaced by the corresponding ester, or more generally, is a molecule that has both peptide and ester linkages in proximity in the same amino acid-containing small molecule or chain.

In vitro: Previous study found that luzopeptin A treatment could produce additional DNA bands which were the products of type II biintercalation. The types of restriction fragments involved were identified. Maximal type II biintercalation occurred at a luzopeptin A/DNA range of 0.14 to 0.18, at which more than 50% of the total DNA molecules were involved. Type II products were gradually converted to type I products upon prolonged incubation at 37 degrees, maybe due to the tendency for intermolecular bonds to disrupt. Echinomycin treatment failed to produce type II products, probably because of a DNA-binding affinity weaker than that of luzopeptin A [1].

In vivo: Animal study showed that when administered as a suspension in 0.9% NaCl solution, luzopeptin A demonstrated good activity against i.p. B16 melanoma and i.p. P388 leukemia and weak activity versus i.v. P388, i.p. L1210 leukemia, Lewis lung, and Madison 109 lung carcinomas. In terms of tumor cell kill, luzopeptin A induced net reductions in the body burdens of L1210 and P388 leukemias following single-drug injections but failed to yield net reductions following multiple-injection therapies [2].

Clinical trial: So far, no clinical study has been conducted.

References:
[1] Huang, C. H.,Mirabelli, C.K.,Mong, S., et al. Intermolecular cross-linking of DNA through bifunctional intercalation of an antitumor antibiotic, luzopeptin A (BBM-928A). Cancer Research 43, 2718-2724 (1983).
[2] Rose WC, Schurig JE, Huftalen JB, Bradner WT.  Experimental antitumor activity and toxicity of a new chemotherapeutic agent, BBM 928A. Cancer Res. 1983 Apr;43(4):1504-10.